Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Repligen to $220 from $251 and keeps a Buy rating on the shares following quarterly results. The firm cites near-term headwinds to growth and margins, but notes the base business remains healthy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN:
